Physician profile
John Demopulos
NPI 1043233604
$243.90
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $94.95 · 2022: $12.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $118.41 | 2019-2021 | |
| Novo Nordisk INC | $26.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.58 | 2019 | |
| Abbvie INC. | $12.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.39 | 2019 | |
| Amgen INC. | $12.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.90 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.98 | 2019 | |
| Pfizer INC. | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Demopulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.